GRAIL and University of Oxford present results from first prospective study of multi-cancer early detection in a symptomatic patient population at 2023 ASCO annual meeting
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, and the University of Oxford announced results from the prospective SYMPLIFY study during an oral session on Saturday, June 3, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. SYMPLIFY is the first large-scale evaluation of a multi-cancer early detection (MCED) test in individuals who presented to primary care and were referred for diagnostic follow-up for suspicion of cancer.